ArticleBiochemical genetics2026
FABP7 Enhances Endometrial Cancer Cell Migration and Stemness by Activating the Wnt/β-catenin Pathway.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The CCT6A paradigm: biomarker potential and therapeutic challenges in oncology and beyond.Molecular biology reports · 2026Review
- Expression analysis of epithelial membrane protein 1 (EMP1) gene in kidney stone patients.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is a common malignancy of the female reproductive system and poses a significant threat to women's health. Fatty acid binding protein 7 (FABP7) plays a key role in regulating lipid metabolism, signal transduction, and gene expression, and has been implicated in the progression of various cancers. However, its role in endometrial cancer remains unclear. The mRNA and protein expression levels were assessed by RT-qPCR and western blot analysis. Cell proliferation was evaluated using the CCK-8 and colony formation assays. Cell migration and invasion were assessed through wound healing and Transwell assays, while cancer stemness was evaluated using the sphere formation assay. FABP7 was found to be highly expressed in endometrial cancer cells. Knockdown of FABP7 significantly suppressed cell proliferation, migration, and invasion. Furthermore, FABP7 silencing reduced stemness capacity, as evidenced by diminished sphere-forming ability. Mechanistically, downregulation of FABP7 led to inhibition of the Wnt/β-catenin signaling pathway. This study demonstrates that FABP7 can promote cell migration and stemness in endometrial cancer by activating the Wnt/β-catenin pathway, supporting FABP7 as a potential therapeutic target for the clinical management of endometrial cancer.
Indexed as
Identifiers
41402614What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.